Myriad Deal Provides Capital, Exit Strategy for Crescendo as it Transitions to Commercial Operations | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – Five years after its founding, and less than one year after launching its first product, molecular diagnostics firm Crescendo Bioscience is shifting to full commercialization mode for its test targeting rheumatoid arthritis.

But unlike many other startups that are transitioning from the technology development phase, the South San Francisco, Calif.-based company may not have to worry about how to provide its investors a return on its investment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.